GENFIT, a late-stage biopharmaceutical company, agreed to acquire Versantis, a private Swiss-based clinical stage biotechnology company, for CHF105m. "Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs," Pascal Prigent, GENFIT CEO.